Your browser is no longer supported. Please, upgrade your browser.
Settings
BGNE BeiGene, Ltd. daily Stock Chart
BGNE [NASD]
BeiGene, Ltd.
Index- P/E- EPS (ttm)-9.61 Insider Own0.11% Shs Outstand63.07M Perf Week-2.84%
Market Cap8.38B Forward P/E- EPS next Y-10.36 Insider Trans- Shs Float58.91M Perf Month4.68%
Income-502.20M PEG- EPS next Q-2.64 Inst Own77.50% Short Float2.50% Perf Quarter-17.30%
Sales157.70M P/S53.17 EPS this Y43.60% Inst Trans7.31% Short Ratio2.75 Perf Half Y-19.48%
Book/sh34.63 P/B3.84 EPS next Y- ROA-29.60% Target Price196.18 Perf Year42.03%
Cash/sh32.25 P/C4.12 EPS next 5Y24.00% ROE-38.80% 52W Range92.04 - 220.10 Perf YTD36.04%
Dividend- P/FCF- EPS past 5Y- ROI-11.70% 52W High-39.60% Beta-
Dividend %- Quick Ratio11.50 Sales past 5Y- Gross Margin85.70% 52W Low44.44% ATR8.57
Employees1700 Current Ratio11.60 Sales Q/Q-75.40% Oper. Margin- RSI (14)48.12 Volatility6.05% 6.35%
OptionableYes Debt/Eq0.10 EPS Q/Q-199.60% Profit Margin- Rel Volume0.97 Prev Close133.44
ShortableYes LT Debt/Eq0.10 EarningsNov 12 AMC Payout- Avg Volume536.35K Price132.94
Recom1.60 SMA20-3.89% SMA502.45% SMA200-17.45% Volume520,529 Change-0.37%
Nov-21-18Initiated JP Morgan Overweight $174
Sep-25-18Initiated Leerink Partners Outperform
May-17-18Reiterated Maxim Group Buy $200 → $225
May-14-18Initiated Credit Suisse Outperform
Apr-13-18Initiated Piper Jaffray Overweight $200
Apr-10-18Reiterated Maxim Group Buy $160 → $200
Mar-01-18Reiterated Maxim Group Buy $144 → $160
Nov-14-17Downgrade Robert W. Baird Outperform → Neutral $58 → $83
Sep-28-17Reiterated Maxim Group Buy $77 → $120
Aug-07-17Initiated Ladenburg Thalmann Buy $81
Jul-06-17Reiterated Maxim Group Buy $57 → $73
Jul-05-17Reiterated Maxim Group Buy $52 → $57
Sep-22-16Initiated Maxim Group Buy $41
Feb-29-16Initiated Robert W. Baird Outperform $44
Feb-29-16Initiated Morgan Stanley Overweight
Feb-29-16Initiated Goldman Buy $33
Dec-17-18 06:28AM  BRIEF-Beigene Initiates Two Global Phase 3 Front-Line Clinical Trials Of Tislelizumab Reuters
06:00AM  BeiGene Initiates Two Global Phase 3 Front-Line Clinical Trials of Tislelizumab, in Patients with Gastric Cancer and in Patients with Esophageal Cancer GlobeNewswire
Dec-15-18 02:30AM  BeiGene Announces Updated Phase 1A/1B Data on Tislelizumab Presented at the European Society for Medical Oncology Immuno-Oncology Congress GlobeNewswire
Dec-12-18 12:38AM  Is BeiGene, Ltd. (BGNE) Going to Burn These Hedge Funds? Insider Monkey
Dec-10-18 06:05AM  BeiGene to Present Clinical Data on Anti-PD-1 Antibody Tislelizumab at the European Society for Medical Oncology Immuno-Oncology Congress GlobeNewswire
Dec-09-18 04:46PM  Here's Why BeiGene Stock Rose 21.7% in November Motley Fool
Dec-05-18 07:00AM  BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Dec-03-18 02:15PM  BeiGene Presents Clinical Results of Tislelizumab in Relapsed/Refractory Classical Hodgkins Lymphoma at the 60th American Society of Hematology Annual Meeting GlobeNewswire
Dec-01-18 03:45PM  BeiGene Announces Clinical Results of Zanubrutinib in Mantle Cell Lymphoma From Two Presentations at the 60th American Society of Hematology Annual Meeting GlobeNewswire
Nov-30-18 04:05PM  Chinese biotech stocks hit by a double whammy, which means its time to buy MarketWatch +6.53%
06:06AM  Can The Uptrend Continue for BeiGene (BGNE)? Zacks
Nov-28-18 09:00AM  Report: Exploring Fundamental Drivers Behind Matrix Service, NantHealth, Earthstone Energy, Jounce Therapeutics, BeiGene, and Oxford Immunotec Global New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
08:39AM  Earnings Estimates Moving Higher for BeiGene (BGNE): Time to Buy? Zacks
Nov-27-18 06:58AM  BRIEF-Zymeworks, Beigene Announce License And Collaboration Agreement For Zymeworks' Her2-Targeted Therapeutic Candidates Reuters
06:30AM  Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks Azymetric and EFECT Platforms Globally Business Wire
Nov-21-18 02:53PM  Analysts Take Action on Health Care Stocks GuruFocus.com
Nov-20-18 07:00AM  BeiGene to Present at the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-16-18 07:00AM  BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology GlobeNewswire
Nov-15-18 08:54AM  BeiGene (BGNE) Catches Eye: Stock Jumps 8.3% Zacks
07:00AM  Priority Review Granted to BeiGenes New Drug Applications for Zanubrutinib and Tislelizumab in China GlobeNewswire
Nov-13-18 07:00AM  BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-08-18 04:32PM  Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors PR Newswire
Nov-07-18 05:36PM  BRIEF-Beigene Initiates Global Head-To-Head Phase 3 Clinical Trial Of Zanubrutinib Reuters
07:00AM  BeiGene Reports Third Quarter 2018 Financial Results GlobeNewswire
07:00AM  BeiGene Initiates Global Head-to-Head Phase 3 Clinical Trial of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma GlobeNewswire
Nov-05-18 07:00AM  BeiGene to Present Clinical Data on PARP Inhibitor Pamiparib at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology GlobeNewswire
Nov-02-18 04:11AM  Chinas Innovent Extends Gain from Solid HK IPO Investing.com
Nov-01-18 09:00AM  BeiGene to Present Clinical Data on Tislelizumab and Zanubrutinib at the 60th American Society of Hematology Annual Meeting GlobeNewswire
08:00AM  Today's Research Reports on Trending Tickers: Gilead Sciences and BeiGene ACCESSWIRE
Oct-24-18 07:05AM  BRIEF-Beigene Announces Acceptance Of Its New Drug Application In China Reuters -5.82%
07:00AM  BeiGene Announces Acceptance of its New Drug Application in China and Top-Line Pivotal Data for Zanubrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma GlobeNewswire
Oct-22-18 08:49AM  BRIEF-Beigene Presents Preliminary Clinical Trial Data In Patients With Solid Tumors Reuters -5.86%
08:18AM  BeiGene (BGNE): Moving Average Crossover Alert Zacks
07:15AM  BeiGene Presents Preliminary Clinical Data on PARP Inhibitor Pamiparib in Combination with Low-Dose Temozolomide in Patients with Solid Tumors at European Society for Medical Oncology (ESMO) 2018 Congress GlobeNewswire
Oct-19-18 07:45AM  Detailed Research: Economic Perspectives on BeiGene, Costco Wholesale, Rogers, Advance Auto Parts, Celcuity, and Harris What Drives Growth in Today's Competitive Landscape GlobeNewswire
Oct-12-18 07:33AM  BRIEF-Beigene Announces Updated Results From Phase 1 Clinical Trial Of Zanubrutinib Reuters
06:00AM  BeiGene Announces Updated Results from Phase 1 Clinical Trial of Zanubrutinib in Patients with Waldenströms Macroglobulinemia GlobeNewswire
Oct-11-18 06:42AM  BRIEF-MEI Pharma And Beigene Announce Clinical Collaboration Reuters
06:00AM  MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies PR Newswire
Oct-10-18 07:35AM  BRIEF-Beigene Announces National Reimbursement Inclusion Of Vidaza® (Azacitidine For Injection) By The State Medical Insurance Administration In China Reuters -8.45%
06:00AM  BeiGene Announces National Reimbursement Inclusion of VIDAZA® (Azacitidine for Injection) by the State Medical Insurance Administration in China GlobeNewswire
Oct-08-18 06:05PM  BeiGene to Present Clinical Data on Zanubrutinib and Pamiparib at Upcoming Medical Meetings GlobeNewswire
Oct-01-18 06:00PM  BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-27-18 06:00AM  3 Biotechs Poised for 10% Gains Investopedia
Sep-25-18 06:00AM  BeiGene to Present at Upcoming Investor Conferences GlobeNewswire
Sep-21-18 09:26PM  BRIEF-Beigene Announces Preliminary Results From The Phase 1 Clinical Trial Of Zanubrutinib Reuters
08:30PM  BeiGene Announces Preliminary Results from the Phase 1 Clinical Trial of Zanubrutinib in Chinese Patients with B-Cell Lymphoma at Annual Meeting of the Chinese Society of Clinical Oncology GlobeNewswire
Sep-20-18 11:38PM  BeiGene Presents Results on Anti-PD-1 Antibody Tislelizumab in Chinese Patients with Lung Cancers at the Annual Meeting of the Chinese Society of Clinical Oncology GlobeNewswire
04:49AM  BRIEF-Beigene Presents Preliminary Results On Tislelizumab Reuters
04:45AM  BeiGene Presents Preliminary Results on Anti-PD-1 Antibody Tislelizumab in Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors at Annual Meeting of the Chinese Society of Clinical Oncology GlobeNewswire
Sep-18-18 07:26AM  BRIEF-Beigene Selects GE Healthcare's Biologics Factory To Boost Manufacturing Capacity Reuters
Sep-16-18 06:00PM  BeiGene Announces Oral Data Presentations at Annual Meeting of the Chinese Society of Clinical Oncology GlobeNewswire
Sep-06-18 06:56PM  [$$] SpringWorks Joins BeiGene in Cancer Drug Collaboration The Wall Street Journal
06:09AM  BRIEF-Beigene And Springworks Therapeutics Collaborate To Evaluate Targeted Combination Therapy In Advanced Solid Tumors Reuters
06:00AM  BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors Business Wire
Sep-05-18 05:05PM  BeiGene to Present Data on Anti-PD-1 Antibody Tislelizumab at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto GlobeNewswire
Sep-04-18 05:00PM  BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
06:00AM  BeiGene to Present at the Morgan Stanley 16th Annual Global Healthcare Conference GlobeNewswire
Aug-31-18 06:00AM  BeiGene Announces Acceptance of New Drug Application for Anti-PD-1 Antibody Tislelizumab in Hodgkins Lymphoma in China GlobeNewswire
Aug-26-18 06:00PM  BeiGene Announces Acceptance of its First New Drug Application for Zanubrutinib in Relapsed/Refractory Mantle Cell Lymphoma by China Drug Administration GlobeNewswire
Aug-24-18 02:00PM  3 Biotech Stocks That May Rise as Much as 16% Investopedia
Aug-09-18 05:11AM  BRIEF-Beigene Initiates New Phase 3 Trial Of Anti-Pd-1 Antibody Tislelizumab Combined With Chemotherapy Reuters
05:08AM  BRIEF-Beigene Ltd Q2 Loss Per Share $0.22 Reuters
05:05AM  BeiGene Reports Second Quarter 2018 Financial Results GlobeNewswire
05:05AM  BeiGene Initiates New Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer in China PR Newswire
Aug-08-18 04:05PM  BeiGene Announces Closing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering GlobeNewswire
01:12AM  BeiGene's CEO on HK Debut, China Growth Strategy, Regulation Bloomberg Video
01:12AM  BeiGene's CEO on HK Debut, China Growth Strategy, Regulation Bloomberg
Aug-07-18 11:32PM  China Tower, BeiGene Make Trading Debut in Hong Kong Bloomberg Video
11:32PM  China Tower, BeiGene Make Trading Debut in Hong Kong Bloomberg
10:32PM  BeiGene founder on the timing of the company's IPO CNBC Videos
09:25PM  BRIEF-Shares Of Beigene Set To Open On Hong Kong Debut Flat At HK$108.00 Reuters
06:00PM  Zero-Sales Biotechs May Damage Your Financial Health Bloomberg
Aug-06-18 12:54AM  Hong Kong stocks can't escape US-China trade war's 'very long shadow' CNBC
Aug-04-18 06:03PM  Here's Why BeiGene Rose 23.4% in July Motley Fool
Aug-02-18 07:39AM  [$$] Chinese Cancer-Drugmaker Raises $900 Million in Hong Kong Listing The Wall Street Journal
06:57AM  BRIEF-Beigene Announces Pricing Of its Hong Kong IPO And Global Offering Reuters
06:44AM  BeiGene Announces Pricing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering GlobeNewswire
12:51AM  Chinese biotech BeiGene raises $903 million in Hong Kong's first secondary listing under new rules - sources Reuters
12:45AM  Chinese biotech BeiGene raises $903 mln in HK's first secondary listing under new rules -sources Reuters
Aug-01-18 02:08AM  HKEX chief welcomes secondary listings while China finalises CDRs Reuters
Jul-27-18 08:19AM  BRIEF-Beigene Anticipates That The Public Offering Price Will Be Between Hk$94.40 And Hk$111.60 Per Share, Or Between About $12.03 And $14.22 Per Reuters
07:08AM  BeiGene Announces Proposed Hong Kong Initial Public Offering and Global Offering GlobeNewswire
Jul-24-18 04:30PM  BeiGene Initiates Phase 3 Pivotal Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer in China GlobeNewswire
07:00AM  BeiGene Initiates Global Phase 3 Trial of PARP Inhibitor Pamiparib in Patients with Advanced Gastric Cancer GlobeNewswire
Jul-23-18 08:00AM  Today's Research Reports on Trending Tickers: Celgene and BeiGene ACCESSWIRE
Jul-22-18 04:30PM  BeiGene Announces Preliminary Topline Results of Pivotal Trial in China for Anti-PD-1 Antibody Tislelizumab in Hodgkins Lymphoma GlobeNewswire
04:30PM  BeiGene Announces Plan to Pursue Accelerated Approval in the U.S. of BTK Inhibitor Zanubrutinib in Waldenström Macroglobulinemia (WM) GlobeNewswire
Jul-20-18 04:47AM  BeiGene Attends Hearing Before the Listing Committee of the Stock Exchange of Hong Kong Limited GlobeNewswire
Jul-03-18 10:45PM  3 Reasons BeiGene Needs to Be on Your Radar Motley Fool
04:05PM  BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jun-19-18 05:00AM  Chinas Getting Ready to Take On the Worlds Biggest Drugmakers Bloomberg
05:00AM  China Is Getting Ready to Take On the Worlds Biggest Drugmakers Bloomberg
Jun-15-18 02:00AM  BeiGene Provides Development Update and Presents Clinical Data on Zanubrutinib at the 23rd Congress of the European Hematology Association GlobeNewswire
Jun-06-18 07:00AM  BeiGene to Present at the Goldman Sachs 39th Annual Global Healthcare Conference GlobeNewswire
Jun-05-18 07:00AM  BeiGene to Present at the William Blair 2018 Growth Stock Conference GlobeNewswire
Jun-01-18 07:00AM  BeiGene to Present Data on Zanubrutinib and Host an Investor Call from the 23rd Congress of the European Hematology Association GlobeNewswire
May-21-18 07:40AM  Blog Exposure - BeiGene Commenced Phase-3 Trial of Pamiparib in China ACCESSWIRE
May-19-18 11:49AM  These Stocks Have Quadrupled in Just 1 Year Motley Fool
May-17-18 07:00AM  BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Chinese Patients with Ovarian Cancer GlobeNewswire
BeiGene, Ltd. develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway; BGB-A333, an humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; and MGCD-0516, a multi-kinase inhibitor. Its preclinical programs consists of therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has strategic collaborations with Celgene Corporation to research and develop BeiGene, Ltd.'s investigational anti-programmed cell death protein 1 inhibitor, BGB-A317; Merck KGaA to research and develop on BGB-290 and BGB-283; and MEI Pharma, Inc. to evaluate the safety and efficacy of ME-401, an investigational PI3K delta inhibitor in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OYLER JOHNChief Executive OfficerDec 10Sale135.784,138561,8630Dec 12 05:28 PM
Wang XiaodongDirectorDec 03Sale152.415,000762,0610Dec 04 05:35 PM
OYLER JOHNChief Executive OfficerNov 28Sale147.198,8651,304,8624,138Nov 28 07:26 PM
OYLER JOHNChief Executive OfficerNov 27Sale144.5711,2521,626,74313,003Nov 28 07:26 PM
Huang JaneCMO, HematologyNov 26Option Exercise29.493,00088,4703,000Nov 28 07:25 PM
OYLER JOHNChief Executive OfficerNov 26Sale139.069,0781,262,43024,255Nov 28 07:26 PM
Huang JaneCMO, HematologyNov 26Sale139.583,000418,7500Nov 28 07:25 PM
Wang XiaodongDirectorNov 19Sale124.305,000621,4900Nov 21 06:41 PM
Peterson Amy C.CMO, Immuno-oncologyNov 12Option Exercise29.1012,067351,15012,067Nov 13 10:20 AM
Peterson Amy C.CMO, Immuno-oncologyNov 12Sale112.7312,0671,360,3490Nov 13 10:20 AM
Peterson Amy C.CMO, Immuno-oncologyNov 09Option Exercise29.1013,222384,76013,222Nov 13 10:20 AM
Peterson Amy C.CMO, Immuno-oncologyNov 09Sale120.4913,2221,593,1630Nov 13 10:20 AM
Peterson Amy C.CMO, Immuno-oncologyNov 08Option Exercise29.1014,711428,09014,711Nov 13 10:20 AM
Peterson Amy C.CMO, Immuno-oncologyNov 08Sale126.0714,7111,854,5770Nov 13 10:20 AM
Huang JaneCMO, HematologySep 04Sale174.602,911508,2470Sep 05 05:15 PM
Glazer Donald W.DirectorAug 30Sale179.001,000179,00013,384Aug 31 04:54 PM
Glazer Donald W.DirectorAug 29Sale179.001,000179,00014,384Aug 31 04:54 PM
Peterson Amy C.CMO, Immuno-oncologyAug 23Sale169.125,769975,6660Aug 24 04:25 PM
Wang XiaodongDirectorAug 13Sale158.773,449547,5910Aug 15 04:23 PM
BAKER BROS. ADVISORS LPDirectorAug 02Buy108.005,814,100627,922,8005,250,491Aug 06 05:22 PM
OYLER JOHNChief Executive OfficerJul 16Sale164.122,550418,4970Jul 17 05:02 PM
Liang HowardCFO & Chief Strategy OfficerMar 19Option Exercise6.5024,128156,83229,128Mar 20 05:02 PM
Liang HowardCFO & Chief Strategy OfficerMar 19Sale161.4629,1284,702,9850Mar 20 05:02 PM
Liang HowardCFO & Chief Strategy OfficerMar 16Option Exercise6.5010,87270,66815,872Mar 20 05:02 PM
Liang HowardCFO & Chief Strategy OfficerMar 16Sale157.0710,8721,707,6665,000Mar 20 05:02 PM
OYLER JOHNChief Executive OfficerMar 02Sale148.1325,3623,756,7840Mar 02 06:42 PM
OYLER JOHNChief Executive OfficerMar 01Sale143.0839,3005,623,20525,362Mar 02 06:42 PM
Li JiEVP and Gl. Head of Bus. Dev.Feb 28Option Exercise26.6510,000266,50010,000Mar 02 06:41 PM
Li JiEVP and Gl. Head of Bus. Dev.Feb 28Sale146.8810,0001,468,7600Mar 02 06:41 PM
OYLER JOHNChief Executive OfficerFeb 28Sale146.6934,3385,036,94364,662Mar 02 06:42 PM
BAKER BROS. ADVISORS LPDirectorJan 18Buy101.001,980,198199,999,9985,121,404Jan 22 05:03 PM
OYLER JOHNChief Executive OfficerDec 26Sale96.4620,1371,942,51599,000Dec 28 05:49 PM
Huang JaneCMO, HematologyDec 21Option Exercise29.511,00029,5101,000Dec 22 04:43 PM
Huang JaneCMO, HematologyDec 21Sale98.001,00098,0000Dec 22 04:43 PM